Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae

Chemotherapy

Volumn 47, Issue 2, 2001, Pages 90-96

  Esposito, Silvano ^a,b   Noviello, Silvana ^a   Ianniello, Filomena ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Clinica Malattie Infettive   (Italy)

Author keywords

Macrolides; Moxifloxacin; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; SPARFLOXACIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CEFOTAXIME; CEFUROXIME; CIPROFLOXACIN; ERYTHROMYCIN; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES; STREPTOCOCCUS PNEUMONIAE; TEICOPLANIN; VANCOMYCIN;

EID: 0035121461     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048506     Document Type: Article

References (33)

1. Immunization policies and vaccine coverage among adults
2. The epidemiology of pneumococcal disease in infants and children
3. Development of resistance to penicillin by pneumococci
4. Susceptibility of pneumococci to nine antibiotics
5. Resistant pneumococcus
6. Relapsing pneumococcal meningitis: Isolation of an organism with decreased susceptibility to penicillin G
7. Activity of CP-99219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology
8. Pneumococcal resistance to antibiotics
9. Antibiotic resistance in Streptococcus pneumoniae
10. Emergence of multiply resistant pneumococci
11. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986
12. International surveillance of resistance among respiratory tract pathogens: Asia and Europe, 1997-1998, abstract EO23
13. Antimicrobial resistance in Streptococcus pneumoniae: An overview
14. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to β-lactam antibiotics
15. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone
16. Analysis of penicillin and cephalosporin-resistant Streptococcus pneumoniae isolates: Relatedness of US isolates and comparison of penicillin binding protein, abstract 104
17. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis
18. Penicillin susceptibility of Streptococcus pneumoniae in a private pediatric hospital in Houston, Texas
19. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use
20. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: A population-based study
21. In-vitro development of resistance to β-lactam antibiotics in Streptococcus pneumoniae
22. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study
23. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe
24. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993
25. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniaeto RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin and ciprofloxacin
26. Infectious complications with respiratory pathogens despite ciprofloxacin therapy
27. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability
28. Microbial etiology of acute pneumonia in hospitalized patients
29. Lower respiratory tract infection therapy - The role of ciprofloxacin
30. New quinolones and gram-positive bacteria
31. Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997-1998, abstract EO22
32. Activity of ciprofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis: Has it changed in the last decade?